Pulmonary arterial hypertension in systemic sclerosis.

[1]  A. Mantero,et al.  [Pulmonary hypertension in autoimmune rheumatic diseases]. , 2011, Reumatismo.

[2]  O. Distler,et al.  Are tyrosine kinase inhibitors promising for the treatment of systemic sclerosis and other fibrotic diseases? , 2010, Swiss medical weekly.

[3]  P. Shenoy,et al.  Phosphodiesterase inhibitors in the management of autoimmune disease. , 2010, Autoimmunity reviews.

[4]  L. Mouthon,et al.  Geoepidemiology of systemic sclerosis. , 2010, Autoimmunity reviews.

[5]  Sanjiv J. Shah,et al.  Carbon monoxide diffusing capacity and mortality in pulmonary arterial hypertension. , 2010, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[6]  I. Morecroft,et al.  In vivo effects of a combined 5-HT1B receptor/SERT antagonist in experimental pulmonary hypertension. , 2010, Cardiovascular research.

[7]  P. Hassoun,et al.  Therapy for pulmonary arterial hypertension associated with systemic sclerosis , 2009, Current opinion in rheumatology.

[8]  Sanjiv J. Shah,et al.  Selective serotonin reuptake inhibitors and the incidence and outcome of pulmonary hypertension. , 2009, Chest.

[9]  E. Zakynthinos,et al.  Serum VEGF levels are related to the presence of pulmonary arterial hypertension in systemic sclerosis , 2009, BMC pulmonary medicine.

[10]  Y. Allanore,et al.  N-terminal pro brain natriuretic peptide: the new cornerstone of cardiovascular assessment in systemic sclerosis. , 2009, Clinical and experimental rheumatology.

[11]  P. Hassoun.  Therapies for scleroderma-related pulmonary arterial hypertension , 2009, Expert review of respiratory medicine.

[12]  P. Corris,et al.  Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. , 2009, American journal of respiratory and critical care medicine.

[13]  M. Trojanowska.  Role of PDGF in fibrotic diseases and systemic sclerosis. , 2008, Rheumatology.

[14]  R. Silver.  Endothelin and scleroderma lung disease. , 2008, Rheumatology.

[15]  O. Distler,et al.  Intracellular tyrosine kinases as novel targets for anti-fibrotic therapy in systemic sclerosis. , 2008, Rheumatology.

[16]  D. Veale,et al.  Biomarkers in systemic sclerosis. , 2008, Rheumatology.

[17]  Xiu-zhen Sun,et al.  Statins suppress MMP2 secretion via inactivation of RhoA/ROCK pathway in pulmonary vascular smooth muscles cells. , 2008, European journal of pharmacology.

[18]  G. Simonneau,et al.  Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial , 2008, The Lancet.

[19]  C. Cheadle,et al.  Identification of candidate genes in scleroderma-related pulmonary arterial hypertension. , 2008, Translational research : the journal of laboratory and clinical medicine.

[20]  P. Postmus,et al.  Nailfold capillary density is associated with the presence and severity of pulmonary arterial hypertension in systemic sclerosis , 2008, Annals of the rheumatic diseases.

[21]  Alan C. Wilson,et al.  Assessment of pulmonary arterial hypertension in patients with systemic sclerosis: comparison of noninvasive tests with results of right-heart catheterization. , 2008, The Journal of rheumatology.

[22]  D. Ivy,et al.  Short- and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension. , 2008, Journal of the American College of Cardiology.

[23]  M. MacLean.  Pulmonary hypertension and the serotonin hypothesis: where are we now? , 2007, International journal of clinical practice. Supplement.

[24]  D. Celermajer,et al.  Pulmonary arterial hypertension in systemic sclerosis: the need for early detection and treatment , 2007, Internal medicine journal.

[25]  D. Hansell,et al.  Bronchoalveolar lavage cellular profiles in patients with systemic sclerosis-associated interstitial lung disease are not predictive of disease progression. , 2007, Arthritis and rheumatism.

[26]  Y. Shang,et al.  Transplantation of autologous endothelial progenitor cells may be beneficial in patients with idiopathic pulmonary arterial hypertension: a pilot randomized controlled trial. , 2007, Journal of the American College of Cardiology.

[27]  M. Fujimoto,et al.  Increased serum soluble CD40 levels in patients with systemic sclerosis. , 2007, The Journal of rheumatology.

[28]  R. Barst.  A review of pulmonary arterial hypertension: role of ambrisentan , 2007, Vascular health and risk management.

[29]  A. Waxman.  A review of sitaxsentan sodium in patients with pulmonary arterial hypertension , 2007, Vascular health and risk management.

[30]  U. Müller-Ladner,et al.  Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database , 2007, Annals of the rheumatic diseases.

[31]  C. Ricachinevsky,et al.  Treatment of pulmonary arterial hypertension. , 2006, Jornal de pediatria.

[32]  J. Granton,et al.  Anticoagulation in pulmonary arterial hypertension: a qualitative systematic review , 2006, European Respiratory Journal.

[33]  H. Kantarjian,et al.  Biology of platelet-derived growth factor and its involvement in disease. , 2006, Mayo Clinic proceedings.

[34]  J. Krishnan,et al.  Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. , 2006, Arthritis and rheumatism.

[35]  M. Humbert,et al.  Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. , 2006, Chest.

[36]  M. Humbert,et al.  Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions , 2006, Annals of the rheumatic diseases.

[37]  V. Seifert,et al.  Ambrisentan, a non-peptide endothelin receptor antagonist. , 2006, Cardiovascular drug reviews.

[38]  K. Brown,et al.  Collagen Vascular Diseases of the Lung , 2006 .

[39]  M. Humbert,et al.  Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. , 2005, Arthritis and rheumatism.

[40]  T. Fleming,et al.  Sildenafil citrate therapy for pulmonary arterial hypertension. , 2005, The New England journal of medicine.

[41]  Francesco Boin,et al.  Understanding, assessing and treating Raynaud's phenomenon , 2005, Current opinion in rheumatology.

[42]  W. Seeger,et al.  Reversal of experimental pulmonary hypertension by PDGF inhibition. , 2005, The Journal of clinical investigation.

[43]  D. Badesch,et al.  Ambrisentan therapy for pulmonary arterial hypertension. , 2005, Journal of the American College of Cardiology.

[44]  M. Iwamoto,et al.  Comparable effects of sildenafil citrate and alprostadil on severe Raynaud's phenomenon in a patient with systemic sclerosis , 2005, Clinical and experimental dermatology.

[45]  P. Scheffler,et al.  Use of tadalafil in a patient with a secondary Raynaud's phenomenon not responding to sildenafil. , 2005, Microvascular research.

[46]  M. Mayes,et al.  Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. , 2004, Arthritis and rheumatism.

[47]  W. Seeger,et al.  Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. , 2004, Journal of the American College of Cardiology.

[48]  W. Seeger,et al.  Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension , 2004 .

[49]  D. Borderie,et al.  Increased plasma soluble CD40 ligand concentrations in systemic sclerosis and association with pulmonary arterial hypertension and digital ulcers , 2004, Annals of the rheumatic diseases.

[50]  M. Humbert,et al.  Cellular and molecular pathobiology of pulmonary arterial hypertension. , 2004, Journal of the American College of Cardiology.

[51]  D. Borderie,et al.  N-terminal pro-brain natriuretic peptide as a diagnostic marker of early pulmonary artery hypertension in patients with systemic sclerosis and effects of calcium-channel blockers. , 2003, Arthritis and rheumatism.

[52]  C. Betsholtz.  Biology of platelet-derived growth factors in development. , 2003, Birth defects research. Part C, Embryo today : reviews.

[53]  S. Rosenkranz,et al.  Sildenafil improved pulmonary hypertension and peripheral blood flow in a patient with scleroderma-associated lung fibrosis and the raynaud phenomenon. , 2003, Annals of internal medicine.

[54]  R. Brook,et al.  Increased asymmetric dimethylarginine and endothelin 1 levels in secondary Raynaud's phenomenon: implications for vascular dysfunction and progression of disease. , 2003, Arthritis and rheumatism.

[55]  G. Funk,et al.  Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. , 2003, The Journal of clinical investigation.

[56]  M. Mayes.  Endothelin and endothelin receptor antagonists in systemic rheumatic disease. , 2003, Arthritis and rheumatism.

[57]  S. Rich,et al.  Efficacy and Safety of Treprostinil: An Epoprostenol Analog for Primary Pulmonary Hypertension , 2003, Journal of cardiovascular pharmacology.

[58]  T. Medsger,et al.  Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. , 2003, Arthritis and rheumatism.

[59]  N. Morrell,et al.  Molecular and cellular basis of pulmonary vascular remodeling in pulmonary hypertension. , 2002, Progress in cardiovascular diseases.

[60]  F. Wigley,et al.  Targeting mediators of vascular injury in scleroderma. , 2002, Current opinion in rheumatology.

[61]  M. Hoeper,et al.  Intravenous iloprost for treatment failure of aerosolised iloprost in pulmonary arterial hypertension , 2002, European Respiratory Journal.

[62]  D. Isenberg,et al.  Pulmonary hypertension in autoimmune rheumatic diseases: where are we now? , 2002, Arthritis and rheumatism.

[63]  W. Seeger,et al.  Inhaled iloprost for severe pulmonary hypertension. , 2002, The New England journal of medicine.

[64]  M. Humbert,et al.  Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. , 2002, Journal of the American College of Cardiology.

[65]  R. Barst,et al.  Bosentan therapy for pulmonary arterial hypertension. , 2002, The New England journal of medicine.

[66]  R. Ekman,et al.  Correlation between plasma concentrations of calcitonin gene related peptide and pulmonary pressure in patients with systemic sclerosis , 2002, Annals of the rheumatic diseases.

[67]  G. Semenza,et al.  Expression of angiogenesis‐related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis , 2001, The Journal of pathology.

[68]  R. Scorza,et al.  Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study. , 2001, Clinical and experimental rheumatology.

[69]  U. Haustein,et al.  Systemic sclerosis-related Raynaud's phenomenon: effects of iloprost infusion therapy on serum cytokine, growth factor and soluble adhesion molecule levels. , 2001, Acta dermato-venereologica.

[70]  R. Scorza,et al.  Novel mode of action of iloprost: in vitro down-regulation of endothelial cell adhesion molecules. , 2001, Prostaglandins & other lipid mediators.

[71]  R. Krasuski,et al.  Inhaled nitric oxide selectively dilates pulmonary vasculature in adult patients with pulmonary hypertension, irrespective of etiology. , 2000, Journal of the American College of Cardiology.

[72]  J. Dawson,et al.  Raised pulmonary artery pressures measured with Doppler echocardiography in rheumatoid arthritis patients. , 2000, Rheumatology.

[73]  Stuart Rich,et al.  Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease , 2000, Annals of Internal Medicine.

[74]  D. Badesch,et al.  Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. , 1999, American journal of respiratory and critical care medicine.

[75]  R. Hesselstrand,et al.  Mortality and causes of death in a Swedish series of systemic sclerosis patients , 1998, Annals of the rheumatic diseases.

[76]  M. Rubenfire,et al.  Inhaled nitric oxide in primary pulmonary hypertension: a safe and effective agent for predicting response to nifedipine. , 1998, Journal of the American College of Cardiology.

[77]  M Abu-Shakra,et al.  Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. , 1996, British journal of rheumatology.

[78]  T. Saji,et al.  Short-term hemodynamic effect of a new oral PGI2 analogue, beraprost, in primary and secondary pulmonary hypertension. , 1996, The American journal of cardiology.

[79]  G. Valesini,et al.  Plasma endothelin-1 levels in patients with systemic sclerosis: influence of pulmonary or systemic arterial hypertension. , 1995, Annals of the rheumatic diseases.

[80]  A Giaid,et al.  Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. , 1995, The New England journal of medicine.

[81]  M. Matucci-Cerinic.  Sensory neuropeptides and rheumatic diseases. , 1993, Rheumatic diseases clinics of North America.

[82]  D. Stewart,et al.  Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. , 1993, The New England journal of medicine.

[83]  R. Ekman,et al.  CGRP and somatostatin modulate chronic hypoxic pulmonary hypertension. , 1992, The American journal of physiology.

[84]  S. Rich,et al.  The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. , 1992, The New England journal of medicine.

[85]  C. Bunker,et al.  Deficiency of calcitonin gene-related peptide in Raynaud's phenomenon , 1990, The Lancet.

[86]  G. Hughes,et al.  Pulmonary hypertension in a lupus clinic: experience with twenty-four patients. , 1990, The Journal of rheumatology.

[87]  M. Lovy,et al.  Relationship between nailfold capillary abnormalities and organ involvement in systemic sclerosis. , 1985, Arthritis and rheumatism.

[88]  J. Hollander.  ARTHRITIS AND ALLIED CONDITIONS , 1949 .

[89]  M. Humbert,et al.  Inflammation in pulmonary arterial hypertension. , 2012, Chest.

[90]  M. Humbert,et al.  Endothelin-1/endothelin-3 ratio: a potential prognostic factor of pulmonary arterial hypertension. , 2007, Chest.

[91]  J. Novotná,et al.  Possible role of matrix metalloproteinases in reconstruction of peripheral pulmonary arteries induced by hypoxia. , 2002, Physiological research.